Literature DB >> 26755811

Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002-2012.

C Pant1, B S Jani1, M Desai1, A Deshpande2, Prashant Pandya1, Ryan Taylor1, R Gilroy1, M Olyaee1.   

Abstract

Hepatorenal syndrome (HRS) is one of the leading causes of hospitalizations in patients with chronic liver disease (CLD). We conducted a retrospective national database study to determine the epidemiology of HRS in hospitalized patients with CLD. Data from a Nationwide Inpatient Sample were extracted from 2002 to 2012 using ICD-9-CM codes related to CLD and HRS. The following outcomes were examined: in-hospital mortality, total charges, length of stay (LOS), patient demographics, procedures, complications, and comorbidities. Statistical analysis including regression was performed to examine factors associated with HRS. During 2002-2012, hospital discharges related to CLD increased from 407,246 to 836,475 with an increase of 37.9% for HRS as a complication in this population. Patients with CLD and HRS had worse outcomes compared with patients with CLD without HRS. This was manifested as a higher mortality rate (32.0% vs 10.3%), increased LOS (median 7 vs 5 days), and increased hospital costs (median $16,000 vs $11,000). Logistic regression demonstrated that HIV/AIDS (adjusted OR 2.9, 95% CI 2.2 to 3.9), pneumonia (aOR 2.8, 95% CI 2.3 to 3.2), and esophageal variceal bleeding (aOR 1.9, 95% CI 1.7 to 2.0) were associated with higher mortality in patients with HRS. Conversely, liver transplantation (aOR 0.1, 95% CI 0.1 to 0.1), transjugular intrahepatic portosystemic shunt (aOR 0.5, 95% CI 0.4 to 0.6), and hospitalization in the Midwest region of the USA (aOR 0.7, 95% CI 0.6 to 0.7) were associated with reduced mortality. The incidence of HRS in hospitalized patients with CLD increased during 2002-2012. HRS is associated with significant mortality and morbidity in these patients.
Copyright © 2016 American Federation for Medical Research.

Entities:  

Keywords:  Ant-CCP; Autoantibodies; Fibromyalgis/Pain Syndromes; Rheumatoid Arthritis

Mesh:

Year:  2015        PMID: 26755811     DOI: 10.1136/jim-d-15-00181

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  2 in total

1.  Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.

Authors:  Kevin Moore; Khurram Jamil; Katharina Verleger; Linlin Luo; Nehemiah Kebede; Marieke Heisen; Shelby Corman; Roberta Leonardi; Rachel Bakker; Christine Maï; Nisreen Shamseddine; Xingyue Huang; Andrew S Allegretti
Journal:  Aliment Pharmacol Ther       Date:  2020-06-04       Impact factor: 8.171

2.  In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample.

Authors:  Wisit Kaewput; Charat Thongprayoon; Carissa Y Dumancas; Swetha R Kanduri; Karthik Kovvuru; Chalermrat Kaewput; Pattharawin Pattharanitima; Tananchai Petnak; Ploypin Lertjitbanjong; Boonphiphop Boonpheng; Karn Wijarnpreecha; Jose L Zabala Genovez; Saraschandra Vallabhajosyula; Caroline C Jadlowiec; Fawad Qureshi; Wisit Cheungpasitporn
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.